Serum magnesium

There are 101 papers on serum magnesium in aging research: 34 trials and 39 observational studies in people, 6 in animals, 21 reviews. The newest story, Oct 27, 2026: “Kidney drug showed no clear short-term effect on minerals in urine”.

Biomarker

101 papers study it20 more mention it49 findings

6 new papers in 30 daysSee all 121 papers on serum magnesium

At a glance

A human cohort study links repeatedly low serum magnesium after traumatic brain injury with higher risks of dementia, cognitive dysfunction and mortality. Another cohort links low levels with intracranial hemorrhage and mortality, while an unadjusted hospital analysis links high levels with in-hospital mortality. Magnesium supplementation trials report increases, but a trial shows no clear overall effect.

49 findings in 32 papers from 1990 to 2026, 10 of them since July 2026

“serum Mg was negatively associated with diastolic BP but not systolic BP (all P<0.05)”
Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled TrialsHypertension (Dallas, Tex. : 1979)2016doi:10.1161/hypertensionaha.116.07664
  • Human trial34
  • Humans39
  • Animals6

Interventions

17

Magnesium

upin humans4no changein humans1

4 studies
  1. Magnesium increases serum magnesium in humans (0.76 ± 0.02 vs 0.69 ± 0.02 mmol/L).

    “Serum magnesium was significantly higher after treatment with magnesium than with placebo (0.76 ± 0.02 vs 0.69 ± 0.02 mmol/L, P <.001), as was urinary magnesium excretion (magnesium/creatinine ratio 0.23 ± 0.03 vs 0.15 ± 0.02, P =.006).”

    Human trialmagnesium gluconate6 weeksn = 12

    Magnesium Supplementation Modulates T-cell Function in People with Type 2 Diabetes and Low Serum Magnesium Levels

    The Journal of clinical endocrinology and metabolism

  2. Magnesium increases serum magnesium in adults with insulin-treated type 2 diabetes and low magnesium levels.

    “Magnesium treatment significantly increased serum magnesium and urinary magnesium excretion compared with placebo.”

    Human trialin adults with insulin-treated type 2 diabetes and low magnesium levelsplasma-serum15 mmol/dayn = 12

    Magnesium Supplementation Modulates T-cell Function in People with Type 2 Diabetes and Low Serum Magnesium Levels

    The Journal of clinical endocrinology and metabolism

  3. Magnesium increases serum magnesium in humans (0.75±0.02 vs 0.70±0.02 mmol/l, p=0.016).

    “Magnesium supplementation increased both mean ± SEM serum magnesium level (0.75±0.02 vs 0.70±0.02 mmol/l, p=0.016)”

    Human trialin people with insulin-treated type 2 diabetes and low serum magnesium, compared with placebooral supplement15 mmol/day6 weeksn = 14

    Oral magnesium supplementation does not affect insulin sensitivity in people with insulin-treated type 2 diabetes and a low serum magnesium: a randomised controlled trial

    Diabetologia

  4. Magnesium increases serum magnesium in humans (0.75±0.02 vs 0.70±0.02 mmol/l).

    “Serum magnesium level was higher after magnesium supplementation compared with placebo (0.75±0.02 vs 0.70±0.02 mmol/l, p=0.016); this was also the case for the urinary magnesium excretion (magnesium/creatinine ratio 0.23±0.02 vs 0.15±0.02, p=0.005).”

    Human trial6 weeksn = 14

    Oral magnesium supplementation does not affect insulin sensitivity in people with insulin-treated type 2 diabetes and a low serum magnesium: a randomised controlled trial

    Diabetologia

  5. Magnesium increases serum magnesium in humans (versus placebo) (0.05 mmol/L elevation (95% CI 0.03, 0.07)).

    “these reductions were accompanied by 0.05 mmol/L (95% confidence interval, 0.03, 0.07) elevation of serum Mg compared with placebo”

    Human trialversus placebomedian 368 mg/dmedian 3 monthsn = 2,028

    Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials

    Hypertension (Dallas, Tex. : 1979)

  6. Magnesium increases serum magnesium in humans (baseline serum magnesium < 1.8 mg/dL).

    “When only the 37 participants with serum magnesium concentrations < 1.8 mg/dL (indication of deficient magnesium status) were analyzed, magnesium supplementation, but not the placebo, increased serum magnesium concentrations.”

    Human trialbaseline serum magnesium < 1.8 mg/dL7 weeksn = 37

    Magnesium supplementation improves indicators of low magnesium status and inflammatory stress in adults older than 51 years with poor quality sleep

    Magnesium research

  7. Magnesium showed no clear effect on serum magnesium in all participants.

    “Magnesium vs placebo supplementation did not significantly affect serum magnesium when all participants were included in the analysis.”

    Human trialin all participants7 weeksn = 96

    Magnesium supplementation improves indicators of low magnesium status and inflammatory stress in adults older than 51 years with poor quality sleep

    Magnesium research

More on Magnesium

Empagliflozin

upin humans2+5.7%

2 studies
  1. Empagliflozin increases serum magnesium in humans (Adults with autosomal dominant polycystic kidney disease; compared with placebo) (+5.7%).

    “Empagliflozin lowered serum uric acid (-26%), increased serum magnesium (+5.7%) and urinary citrate (+78.6%), and reduced blood pressure (-4/-7 mmHg).”

    Human trialAdults with autosomal dominant polycystic kidney disease; compared with placebo10 mg14 daysn = 15

    Kidney drug showed no clear short-term effect on minerals in urine

    Clinical kidney journal

  2. Empagliflozin increases serum magnesium in humans (mean difference 0.26 ± 0.38 mg/dL).

    “Serum potassium and sodium levels remained unchanged, but magnesium levels were increased (mean difference 0.26 ± 0.38 mg/dL, p < 0.0001) ( B, ).”

    Human trialn = 42

    Metabolic and Lipoprotein Changes in Type 2 Diabetes Patients Treated with Empagliflozin

    Biomedicines

  3. Empagliflozin is linked with higher serum magnesium in humans (mean difference 0.26 ± 0.38 mg/dL).

    “Empagliflozin increased serum magnesium (mean difference = 0.26 ± 0.38 mg/dL, p < 0.0001)”

    Humans1 monthn = 42

    Metabolic and Lipoprotein Changes in Type 2 Diabetes Patients Treated with Empagliflozin

    Biomedicines

More on Empagliflozin

Magnesium chloride

upin humans2

2 studies
  1. Magnesium chloride increases serum magnesium in humans (prediabetes and hypomagnesemia) (0.86 ± 0.08 vs. 0.69 ± 0.16 mmol/L, p = 0.002).

    “participants who received magnesium chloride showed higher serum magnesium levels (0.86 ± 0.08 vs. 0.69 ± 0.16 mmol/L, p = 0.002)”

    Human trialprediabetes and hypomagnesemia5% solutionserum3 monthsn = 62

    Oral magnesium supplementation decreases C-reactive protein levels in subjects with prediabetes and hypomagnesemia: a clinical randomized double-blind placebo-controlled trial

    Archives of medical research

  2. Magnesium chloride increases serum magnesium in hypomagnesemic non-diabetic subjects (0.61 ± 0.08 to 0.81 ± 0.08 mmol/l (p<0.0001); controls 0.62 ± 0.08 to 0.61 ± 0.08 mmol/l).

    “magnesium-supplemented subjects significantly increased their serum magnesium levels (0.61 +/- 0.08 to 0.81 +/- 0.08 mmol/l, p<0.0001)”

    Human trialin hypomagnesemic non-diabetic subjects2.5 g daily3 months

    Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial

    Diabetes & metabolism

More on Magnesium chloride

Sucrosomial magnesium

upin humans1

1 study
  1. Sucrosomial magnesium increases serum magnesium in humans (2.11 ± 0.15 vs. 1.94 ± 0.41 mg/dl).

    “Comparing the treatment and control groups, we observed in the first a significant improvement in magnesaemia levels at T1 (2.11 ± 0.15 vs. 1.94 ± 0.41 mg/dl; p < 0.05), with percentage changes from baseline, 13.4% in the treatment group and 3.2% in the control group.”

    Human trial30 days

    Does the association of therapeutic exercise and supplementation with sucrosomial magnesium improve posture and balance and prevent the risk of new falls?

    Aging clinical and experimental research

  2. Sucrosomial magnesium increases serum magnesium in humans (2.11 ± 0.15 vs. 1.94 ± 0.11; p < 0.05).

    “T1 treatment group showed a significant improvement in blood levels of magnesium (2.11 ± 0.15 vs. 1.94 ± 0.11; p < 0.05)”

    Human trialin postoperative patients with lateral fragility fracture of the proximal femur and hypomagnesemia

    Does the association of therapeutic exercise and supplementation with sucrosomial magnesium improve posture and balance and prevent the risk of new falls?

    Aging clinical and experimental research

More on Sucrosomial magnesium

Tofogliflozin

upin humans1

1 study
  1. Tofogliflozin increases serum magnesium in humans (type 2 diabetes and metabolic dysfunction-associated steatotic liver disease) (2.0 ± 0.19 to 2.13 ± 0.18 mg/dL).

    “Tofogliflozin significantly increased serum magnesium (2.0 ± 0.19 to 2.13 ± 0.18 mg/dL)”

    Human trialtype 2 diabetes and metabolic dysfunction-associated steatotic liver disease20 mg/day48 weeks

    Dynamic trajectories of electrolytes and bone metabolism with tofogliflozin and glimepiride: A post-hoc analysis

    Journal of pharmacological sciences

More on Tofogliflozin

Dapagliflozin

upin humans1

1 study
  1. Dapagliflozin increases serum magnesium in humans.

    “Serum magnesium declined less with dapagliflozin”

    Human trialKidney transplant recipients with post-transplant diabetes mellitus; smaller decline versus standard care10 mg daily54 weeks

    Dapagliflozin and 54-week kidney function in kidney transplant recipients with post-transplant diabetes mellitus: a randomized controlled trial

    Diabetes research and clinical practice

More on Dapagliflozin

SGLT2 inhibitors

upin humans1

1 study
  1. SGLT2 inhibitors increase serum magnesium in humans.

    “SGLT2 inhibitors raise serum magnesium modestly”

    Review

    Magnesium in Diabetes Mellitus and Diabetic Kidney Disease

    Journal of clinical medicine

More on SGLT2 inhibitors

Menopause

downin humans1

1 study
  1. Menopause is linked with lower serum magnesium in humans (postmenopausal versus premenopausal women) (2.22±0.56 vs 2.39±0.22 mg/dL).

    “In contrast, serum magnesium was found significantly lower in group-II (2.22±0.56 mg/dL vs. 2.39±0.22 mg/dL; p<0.05).”

    Humanspostmenopausal versus premenopausal womenfemalesn = 110

    The Alteration of Serum Magnesium Levels in Postmenopausal Bangladeshi Women

    Community Based Medical Journal

More on Menopause

Resveratrol

upin humans1

1 study
  1. Resveratrol increases serum magnesium in humans (Postmenopausal for 2.3±1.2 years).

    “Compared with the control group, resveratrol intake was associated with an increase in serum magnesium levels (p 0.05).”

    Human trialPostmenopausal for 2.3±1.2 yearstrans-resveratrolserumfemalesn = 88

    Resveratrol improves cognitive function and quality of life in postmenopausal women

    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego

More on Resveratrol

Ostarine + raloxifene

downin rats1

1 study
  1. Ostarine + raloxifene decreases serum magnesium in rats (ovariectomized rats).

    “Conversely, the combined treatment increased serum phosphorus and luteinizing hormone levels, decreased serum magnesium and calcium”

    Animalsovariectomized ratsserumup to 13 weeksfemales

    Effects of Combined Treatment With Selective Androgen and Estrogen Receptor Modulators Ostarine and Raloxifen on Bone Tissue In Ovariectomized Rats

    Calcified tissue international

More on Ostarine + raloxifene

1975 Japanese diet

upin humans1

1 study
  1. 1975 Japanese diet increases serum magnesium in humans.

    “serum high-density lipoprotein cholesterol (p < 0.05) and serum magnesium levels (p < 0.05) were significantly increased in JD group”

    Human trial28 daysn = 16

    The 1975 Type Japanese Diet Improves Lipid Metabolic Parameters in Younger Adults: A Randomized Controlled Trial

    Journal of oleo science

More on 1975 Japanese diet

Vitamin D

upin humans1

1 study
  1. Vitamin D increases serum magnesium in obese women, not in non-obese women.

    “Vitamin D injection caused a significant increase in serum Magnesium concentration in obese subjects but not in non obese subjects.”

    Human trialin obese women, not in non-obese women600000 IUfemales

    Obesity induced magnesium deficiency can be treated by vitamin D supplementation

    JPMA. The Journal of the Pakistan Medical Association

More on Vitamin D

Magnesium oxide

upin humans1

1 study
  1. Magnesium oxide increases serum magnesium in humans (P < 0.001).

    “Serum magnesium slightly increased compared to pretreatment levels (P < 0.001).”

    Human trialmagnesium oxideserum1000 mg/d6 weeksn = 20

    Oral physiological magnesium supplementation for 6 weeks with 1 g/d magnesium oxide does not affect increased Lp(a) levels in hypercholesterolaemic subjects

    Magnesium research

More on Magnesium oxide

Magnesium-rich diet

upin humans1

1 study
  1. Magnesium-rich diet increases serum magnesium in humans.

    “Mean serum magnesium levels in group B participants were significantly (p less than 0.01) lowered compared to the mean magnesium level in group A participants”

    Human trial10 yearsn = 400

    Effect of dietary magnesium supplementation in the prevention of coronary heart disease and sudden cardiac death

    Magnesium and trace elements

More on Magnesium-rich diet

All 17

Effects

3

Mortality

upin humans1HR 1.29

1 study
  1. Serum magnesium is linked with higher mortality in humans (repeatedly low (< 1.7 mg/dL) vs normal after traumatic brain injury) (HR 1.29).

    “all-cause mortality (HR 1.29, p < 0.001)”

    Humansrepeatedly low (< 1.7 mg/dL) vs normal after traumatic brain injuryserum10 yearsn = 11,716

    U-shaped pattern in the association between serum magnesium levels and long-term dementia risk after traumatic brain injury: a retrospective cohort study

    Frontiers in nutrition

Anemia

mediatesin humans1

1 study
  1. Serum magnesium is linked with anemia in humans (mediation of the traditional dietary pattern–anemia association).

    “The association between dietary patterns and anaemia is mediated by serum magnesium.”

    Humansmediation of the traditional dietary pattern–anemia association

    Dietary pattern, serum magnesium, ferritin, C-reactive protein and anaemia among older people

    Clinical nutrition (Edinburgh, Scotland)

More on Anemia

Response to magnesium supplementation

no changein humans1

1 study
  1. Serum magnesium showed no clear effect on response to magnesium supplementation in humans (baseline serum magnesium and muscle strength as predictors).

    “Baseline values of serum magnesium and muscle strength of participants did not indicate any influences on response to magnesium supplementation.”

    Human trialbaseline serum magnesium and muscle strength as predictors250 mg/day8 weeksfemales

    Does magnesium supplementation improve body composition and muscle strength in middle-aged overweight women? A double-blind, placebo-controlled, randomized clinical trial

    Biological trace element research

Upstream

1

OIT3

upin mice1

1 study
  1. OIT3 increases serum magnesium in mice (shown by knockout; male mice only) (slightly lower serum Mg2+ in knockout males).

    “Although a slightly lower serum Mg2+ concentration was present in male Oit3-/- mice, this effect was not observed in female Oit3-/- mice.”

    Animalsshown by knockout; male mice onlymales

    Genetic drivers of age-related changes in urinary magnesium excretion

    Physiological genomics

More on OIT3

Associations

17

Mortality

upin humans2HR 1.49

2 studies
  1. Serum magnesium predicts mortality in humans (serum magnesium <1.7 mg/dL) (HR, 1.49).

    “all-cause mortality (HR, 1.49; p < 0.001)”

    Humansserum magnesium <1.7 mg/dL5 yearsn = 266,133

    Association of low magnesium status with incident intracranial hemorrhage: a matched-control database study

    Frontiers in nutrition

  2. Serum magnesium is associated with mortality in humans (acute kidney injury) (26.6% vs 17.9%, P = 0.048).

    “those with magnesium levels < 0.8 mmol/L (P = 0.048), and ≥ 1.0 mmol/L (P < 0.001) exhibited higher 28-day mortalities.”

    Humansacute kidney injury<0.8 mmol/L28 daysmalesn = 184

    Dysmagnesemia with acute kidney injury among older adults: clinical characteristics and prognostic importance

    Aging clinical and experimental research

Low bone mineral density

downin humans1OR 0.6

1 study
  1. Serum magnesium is associated with low bone mineral density in humans (training set; per 0.1 mmol/L serum magnesium) (OR 0.600 per 0.1 mmol/L, 95% CI 0.486–0.741).

    “serum magnesium (OR = 0.600 per 0.1 mmol/L; 95% CI: 0.486-0.741, p < 0.001)”

    Humanstraining set; per 0.1 mmol/L serum magnesiumfemalesn = 2,185

    Correlate factors and nomogram model establishment for women with low bone mineral density: a cross-sectional diagnostic prediction model study

    Frontiers in public health

More on Low bone mineral density

Cognitive dysfunction

upin humans1HR 1.43

1 study
  1. Serum magnesium is linked with a higher risk of cognitive dysfunction in humans (repeatedly low (< 1.7 mg/dL) vs normal after traumatic brain injury) (HR 1.43).

    “cognitive dysfunction (HR 1.43, p = 0.009)”

    Humansrepeatedly low (< 1.7 mg/dL) vs normal after traumatic brain injuryserum10 yearsn = 11,716

    U-shaped pattern in the association between serum magnesium levels and long-term dementia risk after traumatic brain injury: a retrospective cohort study

    Frontiers in nutrition

More on Cognitive dysfunction

Vascular dementia

upin humans1HR 1.97

1 study
  1. Serum magnesium is linked with a higher risk of vascular dementia in humans (repeatedly low (< 1.7 mg/dL) vs normal after traumatic brain injury) (HR 1.97).

    “Among the secondary outcomes, associations were observed for vascular dementia (HR 1.97, p = 0.001)”

    Humansrepeatedly low (< 1.7 mg/dL) vs normal after traumatic brain injuryserum10 yearsn = 11,716

    U-shaped pattern in the association between serum magnesium levels and long-term dementia risk after traumatic brain injury: a retrospective cohort study

    Frontiers in nutrition

More on Vascular dementia

Dementia

upin humans1HR 1.62

1 study
  1. Serum magnesium is linked with a higher risk of dementia in humans (repeatedly low (< 1.7 mg/dL) vs normal (1.70-2.20 mg/dL) after traumatic brain injury) (HR 1.62, 95% CI 1.36-1.94).

    “Low magnesium levels were associated with a higher 10-year risk of incident dementia [2.53% vs. 1.78%; hazard ratio (HR) 1.62, 95% confidence interval (CI), 1.36-1.94; p < 0.001].”

    Humansrepeatedly low (< 1.7 mg/dL) vs normal (1.70-2.20 mg/dL) after traumatic brain injuryserum10 yearsn = 11,716

    U-shaped pattern in the association between serum magnesium levels and long-term dementia risk after traumatic brain injury: a retrospective cohort study

    Frontiers in nutrition

More on Dementia

Subarachnoid hemorrhage

upin humans1HR 1.64

1 study
  1. Serum magnesium predicts subarachnoid hemorrhage in humans (serum magnesium <1.7 mg/dL) (HR, 1.64).

    “subarachnoid hemorrhage (HR, 1.64; p < 0.001)”

    Humansserum magnesium <1.7 mg/dL5 yearsn = 266,133

    Association of low magnesium status with incident intracranial hemorrhage: a matched-control database study

    Frontiers in nutrition

More on Subarachnoid hemorrhage

Intracerebral hemorrhage

upin humans1HR 1.79

1 study
  1. Serum magnesium predicts intracerebral hemorrhage in humans (serum magnesium <1.7 mg/dL) (HR, 1.79).

    “as well as intracerebral hemorrhage (HR, 1.79; p < 0.001)”

    Humansserum magnesium <1.7 mg/dL5 yearsn = 266,133

    Association of low magnesium status with incident intracranial hemorrhage: a matched-control database study

    Frontiers in nutrition

More on Intracerebral hemorrhage

Intracranial hemorrhage

upin humans1HR 1.74

1 study
  1. Serum magnesium predicts intracranial hemorrhage in humans (serum magnesium <1.7 mg/dL) (HR, 1.74; 95% CI, 1.59-1.89).

    “Low magnesium status was associated with a higher intracranial hemorrhage risk (HR, 1.74; 95% CI, 1.59-1.89; p < 0.001)”

    Humansserum magnesium <1.7 mg/dL5 yearsn = 266,133

    Association of low magnesium status with incident intracranial hemorrhage: a matched-control database study

    Frontiers in nutrition

More on Intracranial hemorrhage

Prediabetes

downin humans1RR 0.69

1 study
  1. Serum magnesium is associated with prediabetes in humans (Highest versus lowest serum magnesium category in cohort studies) (RR 0.69, 95% CI 0.42–1.02; not significant).

    “this relation was not significant in the case of prediabetes (RR = 0.69; 95%CI: 0.42, 1.02)”

    ReviewHighest versus lowest serum magnesium category in cohort studiesn = 46,190

    Serum magnesium and risk of hyperglycemia, type 2 diabetes, and prediabetes: a systematic review and dose-response meta-analysis of observational studies

    Journal of health, population, and nutrition

More on Prediabetes

Type 2 diabetes

downin humans1RR 0.92

1 study
  1. Serum magnesium is associated with type 2 diabetes in humans (Per 0.20 mmol/L increase in serum magnesium in cohort studies) (RR 0.92, 95% CI 0.87–0.97 per 0.20 mmol/L increase).

    “each 0.20 mmol/L increase in serum magnesium level was associated with lower risk of T2DM (RR = 0.92; 95%CI: 0.87, 0.97) in cohort studies”

    ReviewPer 0.20 mmol/L increase in serum magnesium in cohort studies

    Serum magnesium and risk of hyperglycemia, type 2 diabetes, and prediabetes: a systematic review and dose-response meta-analysis of observational studies

    Journal of health, population, and nutrition

More on Type 2 diabetes

Diastolic blood pressure

downin humans1

1 study
  1. Serum magnesium is associated with diastolic blood pressure in humans.

    “serum Mg was negatively associated with diastolic BP but not systolic BP (all P<0.05)”

    Human trialn = 2,028

    Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials

    Hypertension (Dallas, Tex. : 1979)

More on Diastolic blood pressure

C-reactive protein

downin humans1

1 study
  1. Serum magnesium is associated with C-reactive protein in humans (cross-sectional, at baseline in all participants) (rs = -0.22, P=0.05).

    “Serum magnesium was found to be inversely correlated with hs-CRP (rs =-0.22, P=0.05) in the entire participants at baseline.”

    Human trialcross-sectional, at baseline in all participantsfemales

    Effects of oral magnesium supplementation on inflammatory markers in middle-aged overweight women

    Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences

More on C-reactive protein

Obesity

downin humans1

1 study
  1. Obesity is associated with serum magnesium in humans (at baseline, obese vs non-obese women).

    “Baseline concentrations of serum Magnesium and 25 hydroxy vitamin D in obese individuals was lower than non obese individuals, the former being significant.”

    Human trialat baseline, obese vs non-obese womenfemales

    Obesity induced magnesium deficiency can be treated by vitamin D supplementation

    JPMA. The Journal of the Pakistan Medical Association

More on Obesity

All 17

Funding

1 grant since 2019

National Heart, Lung, and Blood Institute$257K

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Human cohorts link low serum magnesium to intracranial hemorrhage and mortality, and repeatedly low levels after traumatic brain injury to dementia and cognitive dysfunction. A human trial finds empagliflozin raises serum magnesium in type 2 diabetes.

  2. Summary written from the findings.

Latest

Dec 2025: 1Jan 2026: 1Feb 2026: 2Mar 2026: 4Apr 2026: 0May 2026: 2Jun 2026: 2Jul 2026: 5Aug 2026: 4Sep 2026: 2Oct 2026: 7Nov 2026: 030 papers in 12 months
Clinical Kidney Journal

Kidney drug showed no clear short-term effect on minerals in urine

In a crossover trial, 15 adults with autosomal dominant polycystic kidney disease took empagliflozin or placebo for 14 days each.In a crossover trial, 15 adults with autosomal dominant polycystic kidney disease took empagliflozin or placebo for 14 days each.

Randomized trial · 15 peopleKidney

See all 121 papers on serum magnesium